Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 11,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Newborn Clear all

Conditions: Fabry's Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound; Drug · Procedure
Lead sponsor: Versiti Blood Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Conditions: Epidermolysis Bullosa
Interventions: topical BPM31510 3.0% Cream; Drug
Lead sponsor: Shasa Hu; Other
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis, Mucociliary Clearance Defect
Interventions: Symptom driven performance of airway clearance, Continuous daily performance of airway clearance; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Lactose Intolerance, Lactose Intolerant, Lactase Persistence, Pre-Diabetes, Diabetes Mellitus, Type 2
Interventions: Lactose-Containing Milk, Lactose-Free Milk; Dietary Supplement
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Alzheimer's Disease in Down Syndrome
Interventions: Not listed
Lead sponsor: LuMind IDSC Foundation; Other
Eligibility: 25 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 11 more

Conditions: Healthy Lifestyle, Obese, Men
Interventions: Diet, Exercise, Standard care; Other
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: cytarabine, clofarabine, filgrastim, Ex-vivo expanded cord blood progenitor cell infusion, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Nohla Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Moderate to Severe Hypoxic-ischemic Encephalopathy
Interventions: Infusion of hCT-MSC; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 0 Hours to 48 Hours
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: Interviews and Surveys; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 12 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Complex Partial Seizures
Interventions: vigabatrin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease, Anemia, Anemia, Hemolytic, Anemia, Sickle Cell, Hematologic Diseases
Interventions: PROMIS for Pain Management App; Other
Lead sponsor: Julia Finkel; Other
Eligibility: 8 Years to 21 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 5 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Denver, Colorado • Providence, Rhode Island

Conditions: Gout
Interventions: Lesinurad, Placebo, Allopurinol; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 165
States / cities: Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more

Conditions: Hypoxic Ischemic Encephalopathy
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: Up to 24 Hours
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more

Conditions: Neck Pain, Low Back Pain
Interventions: Muscle Pattern Recognition (MPR); Device
Lead sponsor: iTech Medical, Inc.; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Irvine, California • Portage, Michigan • Salt Lake City, Utah

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy; Drug · Genetic · Other + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 1 Year to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sickle Cell Disease
Interventions: ICA-17043; Drug
Lead sponsor: Icagen; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 42
States / cities: Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more

Conditions: Thyroid Eye Disease, TED
Interventions: focus groups and individual interviews as well as filling out questionnaires; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Hemophilia A
Interventions: rVIII-SingleChain; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus, Vehicle cream; Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway
Interventions: Setmelanotide; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Scottsdale, Arizona • San Diego, California • Gainesville, Florida + 10 more

Conditions: Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions: Measuring Right Ventricular Size and Function; Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Atopic Dermatitis
Interventions: Clobetasol propionate 0.05% Topical Oil; Drug
Lead sponsor: Hill Dermaceuticals, Inc.; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Sanford, Florida • Savannah, Georgia • Philadelphia, Pennsylvania + 3 more

Search by objective public record fields.

Analysis of the Nervous System in Patients With Fabry's Disease

Microvascular Blood Flow in Sickle Cell Anemia

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

Milk for Diabetes Prevention

Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

Study of hCT-MSC in Newborn Infants With Moderate or Severe HIE

Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients

SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell Pain

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

Combining Lesinurad With Allopurinol in Inadequate Responders

Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

A Stratified Sickle Event Randomized Trial (ASSERT)

Psychological Burden of Thyroid Eye Disease

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema

Open-Label Extension Study of Setmelanotide

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis